Page last updated: 2024-10-20

pteridines and Sarcoma

pteridines has been researched along with Sarcoma in 2 studies

Sarcoma: A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.

Research Excerpts

ExcerptRelevanceReference
"BI 2536 is a selective and potent small-molecule inhibitor of polo-like kinase 1."6.75Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research ( Aerts, C; Allgeier, A; Blay, JY; Bogaerts, J; Brain, E; De Greve, J; Fontaine, C; Fritsch, H; Hanft, G; Lacombe, D; Machiels, JP; Munzert, G; Rapion, J; Ray-Coquard, I; Schöffski, P; Sleijfer, S; Soria, JC; Wolter, P, 2010)
"BI 2536 is a selective and potent small-molecule inhibitor of polo-like kinase 1."2.75Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research ( Aerts, C; Allgeier, A; Blay, JY; Bogaerts, J; Brain, E; De Greve, J; Fontaine, C; Fritsch, H; Hanft, G; Lacombe, D; Machiels, JP; Munzert, G; Rapion, J; Ray-Coquard, I; Schöffski, P; Sleijfer, S; Soria, JC; Wolter, P, 2010)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Schöffski, P1
Blay, JY1
De Greve, J1
Brain, E1
Machiels, JP1
Soria, JC1
Sleijfer, S1
Wolter, P1
Ray-Coquard, I1
Fontaine, C1
Munzert, G1
Fritsch, H1
Hanft, G1
Aerts, C1
Rapion, J1
Allgeier, A1
Bogaerts, J1
Lacombe, D1
Katoh, S1
Sueoka, T1
Hirayama, K1
Masuda, I1
Nakanishi, N1
Yamada, S1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI)[NCT00526149]Phase 276 participants (Actual)Interventional2007-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for pteridines and Sarcoma

ArticleYear
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Feasibility Studies; Female; Head and Neck Neo

2010

Other Studies

1 other study available for pteridines and Sarcoma

ArticleYear
[Phenylalanine hydroxylating activity in Tawa sarcoma].
    Josai Shika Daigaku kiyo. The Bulletin of the Josai Dental University, 1981, Volume: 10, Issue:1

    Topics: Animals; Biopterins; Hydroxylation; Liver Neoplasms; Neoplasms, Experimental; Phenylalanine Hydroxyl

1981